Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression

Ćeriman Krstić, Vesna (57204881031)Vesna (57204881031)Ćeriman KrstićSoldatović, Ivan (35389846900)Ivan (35389846900)SoldatovićGajić, Milija (57204877678)Milija (57204877678)GajićSamardžić, Natalija (56033770200)Natalija (56033770200)SamardžićStević, Ruža (24823286600)Ruža (24823286600)StevićČolić, Nikola (57201737908)Nikola (57201737908)ČolićLukić, Katarina (59004030300)Katarina (59004030300)LukićŠeha, Biljana (59492355400)Biljana (59492355400)ŠehaRadončić, Damir (59523335400)Damir (59523335400)RadončićStamenić, Slavko (59750966300)Slavko (59750966300)StamenićSavić, Milan (24830640100)Milan (24830640100)SavićMilenković, Vladimir (57224501149)Vladimir (57224501149)MilenkovićMilošević Maračić, Brankica (58313802300)Brankica (58313802300)Milošević MaračićJovanović, Dragana (58721901700)Dragana (58721901700)Jovanović2025-06-122025-06-122025https://doi.org/10.3390/curroncol32040229https://www.scopus.com/inward/record.uri?eid=2-s2.0-105003444375&doi=10.3390%2fcurroncol32040229&partnerID=40&md5=d322b9c19e8c5bad09de5975c2667827https://remedy.med.bg.ac.rs/handle/123456789/494Before the introduction of targeted therapy and immunotherapy, patients with metastatic non-small-cell lung cancer (NSCLC) had a 5-year overall survival (OS) rate of up to 10%. After the positive results of KEYNOTE-024, pembrolizumab was approved in a first-line setting for patients with metastatic NSCLC and PD-L1 ≥ 50%. A small number of patients had a durable response to immunotherapy, and so far it has not been discovered who will benefit. The aim of this study was to investigate the efficacy of first-line pembrolizumab in patients with locally advanced and metastatic NSCLC with high PD-L1 expression in a real-world setting. We enrolled 35 patients with locally advanced and metastatic NSCLC who had PD-L1 ≥ 50%. Progression-free survival was 9 months, 95% CI (2.6–15.4). Overall survival was 14 months, 95% CI (0–28.5). Five-year OS rate for the whole group of patients was 20%, and the six-year OS rate was 17.2%. Immunotherapy was a revolution in the treatment of NSCLC. We still do not know which patients will benefit from immunotherapy, but patients who do respond may experience long-term outcomes. © 2025 by the authors.immunotherapylong-term outcomesNSCLCOSpembrolizumabPFSLong-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression